Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in the United States.1–3 It has been broadly subdivided into 2 categories including nonalcoholic fatty liver, which is considered to be the milder phenotype with lower risk of progression to cirrhosis, and nonalcoholic steatohepatitis (NASH), which is considered to be the more advanced phenotype with substantial risk of progression to cirrhosis.3,4 Recent studies have suggested that some patients with NAFLD may rapidly progress to cirrhosis, irrespective of whether their baseline liver biopsy showed nonalcoholic fatty liver or NASH.